DNA methylation of tumor suppressive mirnas in non-Hodgkin's lymphomas

Frontiers in Genetics

Volumn 3, Issue NOV, 2012, Pages

  Yim, Rita Lok Hay ^a   Kwong, Yok Lam ^a   Wong, Kwan Yeung ^a   Chim, Chor Sang ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

DNA methylation; Lymphoma; Mirna; Tumor suppressor

Indexed keywords

EID: 84876119099     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2012.00233     Document Type: Review

References (69)

1. Agirre, X., Martinez-Climent, J. A., Odero,M.D., and Prosper, E (2012). Epigenetic regulation of miRNA genes in acute leukemia. Leukemia 26, 395-403.
2. Au, W.-Y., Ma, S.-Y., Chim, C.-S., Choy, C., Loong, F., Lie, A. K. W., et al. (2005). Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the world health organization classification scheme: a single center experience of 10 years. Ann. Oncol. 16, 206-214.
3. Bandres, E., Agirre, X., Bitarte, N., Ramirez, N., Zarate, R., Roman-Gomez, J., et al. (2009). Epigenetic regulation of microRNA expression in colorectal cancer. Int. J. Cancer 125, 2737-2743.
4. Botezatu, A., Goia-Rusanu, C. D., Iancu, I. V., Huica, I., Plesa, A., Socolov, D., et al. (2011). Quantitative analysis of the relationship between microRNA-124a,-34b and-203 gene methylation and cervical oncogenesis. Mol. Med. Rep. 4, 121-128.
5. Brown, A. C., Nair, V., and Allday, M. J. (2012). Epigenetic regulation of the latency-associated region of Marek's disease virus in tumor-derived T-cell lines and primary lymphoma. J. Virol. 86,1683-1695.
6. Bueno, M. J., Pérez De Castro, I., Gómez De Cedrón, M., Santos, J., Calin, G. A., Cigudosa Juan, C., et al. (2008). Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell 13,496-506.
7. Calin, G. A., and Croce, C. M. (2009). Chronic lymphocytic leukemia: interplay between noncoding RNAs and protein-coding genes. Blood 114,4761-4770.
8. Callet-Bauchu, E., Baseggio, L., Fel-man, P., Traverse-Glehen, A., Berger, E, Morel, D., et al. (2005). Cyto-genetic analysis delineates a spectrum of chromosomal changes that can distinguish non-MALT marginal zone B-cell lymphomas among mature B-cell entities: a description of 103 cases. Leukemia 19, 1818-1823.
9. Chan, J. K. C. (2001). The new world health organization classification of lymphomas: the past, the present and the future. Hematol. Oncol. 19, 129-150.
10. Chim, C. S., Chan, A. C. L., Choo, C. K., Kwong,Y. L., Lie, A. K. W., and Liang, R. (1998). Mantle cell lymphoma in the Chinese: clinicopathological features and treatment outcome. Am. J. Hematol. 59,295-301.
11. Chim, C. S., Chan, A. C. L., Kwong, Y. L., and Liang, R. (1997). Primary cardiac lymphoma. Am. J. Hematol. 54, 79-83.
12. Chim, C. S., Fung, T. K., Wong, K. E, Lau, J. S., and Liang, R. (2006). Frequent DAP kinase but not p14 or Apaf-1 hypermethylation in B-cell chronic lymphocytic leukemia. J. Hum. Genet. 51, 832-838.
13. Chim, C. S., Hu, W. H. C., Loong, F., Ooi, G. C., and Liang, R. (2003a). GI manifestations of mantle cell lymphoma. Gastrointest. Endosc. 58, 931-933.
14. Chim, C. S., Wong, S. Y., and Kwong, Y L. (2003b). Aberrant gene promoter methylation in acute promye-locytic leukaemia: profile and prognostic significance. Br. J. Haematol. 122,571-578.
15. Chim, C. S., Lau, J. S., Wong, K. E, and Kwong, Y. L. (2005a). CDKN2B methylation is an independent poor prognostic factor in newly diagnosed acute promye-locytic leukemia. Leukemia 20, 149-151.
16. Chim, C. S., Wong, S. Y., Pang, A., Chu, P., Lau, J. S., Wong, K. F., et al. (2005b). Aberrant promoter methylation of the retinoic acid receptor alpha gene in acute promye-locytic leukemia. Leukemia 19, 2241-2246.
17. Chim, C. S., Liang, R., Chan, A. C. L., Kwong, Y L., Ho, E C. S., and Todd, D. (1996). Primary B cell lymphoma of the mediastinum. Hematol. Oncol. 14, 173-179.
18. Chim, C.-S., Ma, S.-Y., Au, W.-Y., Choy, C., Lie, A. K. W., Liang, R., et al. (2004a). Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the international prognostic index. Blood 103,216-221.
19. Chim, C. S., Fung, T. K., Cheung, W. C., Liang, R., and Kwong, Y L. (2004b). SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood 103,4630-4635.
20. Chim, C. S., Ma, S. Y., Au, W Y, Choy, C., Lie, A. K. W., Liang, R., et al. (2004c). Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the international prognostic index. Blood 103,216-221.
21. Chim, C. S., Ooi, G. C., Shek, T. W. H., Liang, R., and Kwong, Y L. (1999). Lethal midline granuloma revisited: nasal T/natural-killer cell lymphoma.J. Clin. Oncol. 17, 1322.
22. Chim, C. S., Tam, C. Y., Liang, R., and Kwong, Y L. (2001a). Methylation of p15 and p16 genes in adult acute leukemia: lack of prognostic significance. Cancer 15,2222-2229.
23. Chim, C. S., Liang, R., Tam, C. Y. Y., and Kwong, Y L. (2001b). Methylation of p15 and p16 genes in acute promyelocytic leukemia: potential diagnostic and prognostic significance. J. Clin. Oncol. 19, 2033-2040.
24. Chim, C. S., Wan, T., Wong, K. Y., Fung, T. K., Drexler, H., and Wong, K. E (2011a). Methylation of miR-34a, miR-34b/c, miR-124-1 and miR-203 in Ph-negative myeloprolifera-tive neoplasms. J. Transl. Med. 9, 197.
25. Chim, C. S., Wong, K. Y., Leung, C. Y., Chung, L. P., Hui, P. K., Chan, S. Y., et al. (2011b). Epigenetic inactivation of the hsa-miR-203 in haematolog-ical malignancies. J. Cell. Mol. Med. 15, 2760-2767.
26. Chim, C. S., Wong, A. S. Y., and Kwong, Y L. (2002). Infrequent hypermethylation of CEBPA promotor in acute myeloid leukaemia. Br. J. Haematol. 119,988-990.
27. Chim, C. S., Wong, K.Y., Qi,Y., Loong, F., Lam, W. L., Wong, L. G., et al. (2010). Epigenetic inactivation of the miR-34a in hematological malignancies. Carcinogenesis 31, 745-750.
28. Choi, J.-H., Li, Y., Guo, J., Pei, L., Rauch, T. A., Kramer, R. S., et al. (2010). Genome-wide DNA methylation maps in follic-ular lymphoma cells determined by methylation-enriched bisulfite sequencing. PLoS ONE 5, e13020. doi:10.1371/journal.pone.0013020
29. Craig, V. J., Cogliatti, S. B., Rehrauer, H., Wündisch,T.,andMüller,A. (2011). Epigenetic silencing of microRNA-203 dysregulates ABL1 expression and drives helicobacter-associated gastric lymphomagenesis. Cancer Res. 71, 3616-3624.
30. Dejean, E., Renalier, M. H., Foisseau, M., Agirre, X., Joseph, N., De Paiva, G. R., et al. (2011). Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas. Leukemia 25, 1882-1890.
31. Desjobert, C., Renalier, M.-H., Bergalet, J., Dejean, E., Joseph, N., Kruczyn-ski, A., et al. (2011). MiR-29a down-regulation in ALK-positive anaplastic large cell lymphomas contributes to apoptosis blockade through MCL-1 overexpression. Blood 117,6627-6637.
32. Duvic, M., and Vu, J. (2007). Vorinos-tat in cutaneous T-cell lymphoma. Drugs Today 43, 585.
33. Fabbri, M., Garzon, R., Cimmino, A., Liu, Z., Zanesi, N., Callegari, E., et al. (2007). MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltrans-ferases 3A and 3B. Proc. Natl. Acad. Sci. U.S.A. 104, 15805-15810.
34. Furuta, M., Kozaki, K.-I., Tanaka, S., Arii, S., Imoto, I., and Inazawa, J. (2010). miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepato-cellular carcinoma. Carcinogenesis 31,766-776.
35. Garcia-Manero, G., and Fenaux, P. (2011). Hypomethylating agents and other novel strategies in myelodys-plastic syndromes. J. Clin. Oncol. 29, 516-523.
36. Garzon, R., Liu, S., Fabbri, M., Liu, Z., Heaphy, C. E. A., Callegari, E., et al. (2009). MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 113, 6411-6418.
37. Gregory, R. I., Yan, K.-P., Amuthan, G., Chendrimada, T., Doratotaj, B., Cooch, N., et al. (2004). The Microprocessor complexmediates the genesis of microRNAs. Nature 432, 235-240.
38. Henry, J., Azevedo-Pouly, A., and Schmittgen, T. (2011). MicroRNA replacement therapy for cancer. Pharm. Res. 28, 3030-3042.
39. Human Genome Sequencing, C. (2004). Finishing the euchromatic sequence of the human genome. Nature 431, 931-945.
40. Iqbal, J., Shen, Y., Liu, Y., Fu, K., Jaffe, E. S., Liu, C., et al. (2012). Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis. Blood 119,4939-4948.
41. Kaneda, M., Okano, M., Hata, K., Sado, T., Tsujimoto, N., Li, E., et al. (2004). Essential role for de novo DNA methyltransferase Dnmt3a in paternal and maternal imprinting. Nature 429, 900-903.
42. Knudson, A. G. (2001). Two genetic hits (more or less) to cancer. Nat. Rev. Cancer 1, 157-162.
43. Kozomara, A., and Griffiths-Jones, S. (2011). miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 39,D152-D157.
44. Kwong, Y. L. (2005). Natural killer-cell malignancies: diagnosis and treatment. Leukemia 19, 2186-2194.
45. Lander, E. S. (2011). Initial impact of the sequencing of the human genome. Nature 470,187-197.
46. Lee, Y., Kim, M., Han, J., Yeom, K.-H., Lee, S., Baek, S. H., et al. (2004). MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 23, 4051-4060.
47. Lehmann, U., Hasemeier, B., Christgen, M., Müller, M., Römermann, D., Länger, F., et al. (2008). Epige-netic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. J. Pathol. 214, 17-24.
48. Lin, Y.-T., Kincaid, R. P., Arasappan, D., Dowd, S. E., Hunicke-Smith, S. P., and Sullivan, C. S. (2010). Small RNA profiling reveals anti-sense transcription throughout the KSHV genome and novel small RNAs. RNA 16, 1540-1558.
49. Liu, J., Carmell, M. A., Rivas, F. V., Marsden, C. G., Thomson, J. M., Song, J.-J., et al. (2004). Arg-onaute2 is the catalytic engine of mammalian RNAi. Science 305, 1437-1441.
50. Lodygin, D., Tarasov, V., Epanchintsev, A., Berking, C., Knyazeva, T., Körner, H.,etal. (2008). Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 7,2591-2600.
51. Lopez-Serra, P., and Esteller, M. (2012). DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer. Oncogene 31, 1609-1622.
52. Lujambio, A., Ropero, S., Ballestar, E., Fraga, M. F., Cerrato, C., Setién, F., et al. (2007). Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res. 67, 1424-1429.
53. Martinez-Climent, J. A., Vizcarra, E., Sanchez, D., Blesa, D., Marugan, I., Benet, I., et al. (2001). Loss of a novel tumor suppressor gene locus at chromosome 8p is associated with leukemic mantle cell lymphoma. Blood 98, 3479-3482.
54. Ng, S.-B., Yan, J., Huang, G., Selvara-jan, V., Tay, J. L.-S., Lin, B., et al. (2011). Dysregulated microRNAs affect pathways and targets of biologic relevance in nasal-type natural killer/T-cell lymphoma. Blood 118, 4919-4929.
55. O'Donnell, K. A., Wentzel, E. A., Zeller, K. I., Dang, C. V., and Mendell, J. T. (2005). c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435, 839-843.
56. Okano, M., Xie, S., and Li, E. (1998). Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat. Genet. 19,219-220.
57. Omura, N., Li, C.-P., Li, A., Hong, S.-M., Walter, K., Jimeno, A., et al. (2008). Genome-wide profiling at methylated promoters in pancreatic ade-nocarcinoma. Cancer Biol. Ther. 7, 1146-1156.
58. Onnis, A., De Falco, G., Antonicelli, G., Onorati, M., Bellan, C., Sherman, O., et al. (2010). Alteration of microR-NAS regulated by c-myc in burkitt lymphoma. PLoS ONE 5, e12960. doi:10.1371/journal.pone.0012960
59. Paik, J. H., Jang, J.-Y., Jeon, Y K., Kim, W. Y., Kim, T. M., Heo, D. S., et al. (2011). MicroRNA-146a downregulates NFΚB activity via targeting TRAF6 and functions as a tumor suppressor having strong prognostic implications in NK/T Cell lymphoma. Clin. Cancer Res. 17, 4761-4771.
60. Reik, W., and Walter, J. (2001). Genomic imprinting: parental influence on the genome. Nat. Rev. Genet. 2, 21-32.
61. Sandoval, J., Heyn, H., Moran, S., Serra-Musach, J., Pujana, M. A., Bibikova, M.,etal. (2011). Validation of aDNA methylation microarray for 450,000 CpG sites in the human genome. Epigenetics 6, 692-702.
62. Shen, L., Kondo, Y., Guo, Y., Zhang, J., Zhang, L., Ahmed, S., et al. (2007). Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters. PLoS Genet. 3, e181. doi:10.1371/journal.pgen.0030181
63. Starczynowski, D. T., Kuchenbauer, F., Argiropoulos, B., Sung, S., Morin, R., Muranyi, A., et al. (2010). Identification of miR-145 and miR-146a as mediators of the 5q-syndrome phenotype. Nat. Med. 16, 49-58.
64. Swerdlow, S. H., Campo, E., Harris, N. L., Jaffe, E. S., Pileri, S. A., Stein, H., et al. (2008). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer.
65. Vose, J. M. (2012). Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management. Am. J. Hematol. 87, 604-609.
66. Wilting, S., Van Boerdonk, R., Henken, E, Meijer, C., Diosdado, B., Mei-jer, G., et al. (2010). Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Mol Cancer 9, 167.
67. Wong, K. Y., So, C. C., Loong, F., Chung, L. P., Lam, W. W L, Liang, R., et al. (2011). Epigenetic inactivation of the miR-124-1 in haematological malignancies. PLoS ONE 6, e19027. doi:10.1371/journal.pone.0019027
68. Xiong, Y., Fang, J.-H., Yun, J.-P., Yang, J., Zhang, Y., Jia, W.-H., et al. (2010). Effects of microRNA-29 on apopto-sis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatol-ogy 51,836-845.
69. Yi, R., Qin, Y., Macara, I. G., and Cullen, B. R. (2003). Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev. 17,3011-3016.